Sodyum fenilasetat ve sodyum benzoat etkileşimleri

Sodyum fenilasetat ve sodyum benzoat (Ammonul) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 49 belgelenmiş etkileşim var: 0 majör, 36 orta, 13 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Orta düzey etkileşimler (36)

  • AspirinNSAİİOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • Aspirin ve dipiridamolantitrombosit ilaçOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • Azelastin ve flutikazonantihistaminikOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • BalsalazidsalisilatOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • BeklometazonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • BetametazonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Bizmut subsalisilatsalisilatOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • BudesonidkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Budesonid ve formoterolkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • DeflazakortkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • DesonidkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • DiflunisalNSAİİOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • FludrokortizonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • FlunisolidkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • FluosinonidkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • FlutikazonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • In a study of adult cancer patients, subjects received sodium phenylacetate administered as a 1-hour infusion twice daily at two dose levels of 125 and 150 mg/kg for a 2-week period. (Gliserol fenilbütirat etiketi, Uyarılar ve önlemler)

  • HalobetazolkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • HidrokortizonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • KlobetazolkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • MesalazinsalisilatOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • MetilprednizolonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • MometazonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Olopatadin ve mometazonantihistaminikOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • PrednizolonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • PrednizonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • SalsalatNSAİİOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • SiklesonidkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • SülfasalazinsülfonamidOrta

    Hyperventilation and Metabolic Acidosis: Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (Sodyum fenilasetat ve sodyum benzoat etiketi, Uyarılar ve önlemler)

  • TriamsinolonkortikosteroidOrta

    Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

Minör değinmeler (13)

  • Amoksisilinpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Amoksisilin ve klavulanatpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Ampisilinpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Ampisilin ve sulbaktampenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Dikloksasilinpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Oksasilinpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Penisilin Gpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Penisilin Vpenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Piperasilin ve tazobaktampenisilin antibiyotikMinör

    Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

  • Valproik asitantikonvülsanMinör

    There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. (Sodyum fenilasetat ve sodyum benzoat etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Sodyum fenilasetat ve sodyum benzoat ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.